Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review

Published:2023-01 Issue:1 Volume:1 Page:46-55
ISSN:2949-7132
Container-title:Cancer Pathogenesis and Therapy
language:en
Short-container-title:Cancer Pathogenesis and Therapy

Author:

Miao Kang,Zhang Li^ORCID

Publisher

Elsevier BV

Reference97 articles.

1. Basic overview of current immunotherapy approaches in cancer;Velcheti;Am Soc Clin Oncol Educ Book,2016

2. Immune escape and immunotherapy of acute myeloid leukemia;Vago;J Clin Invest,2020

3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial;Weber;Lancet Oncol,2015

4. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001;Hamid;Ann Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiorgan Toxicity from Dual Checkpoint Inhibitor Therapy, Resulting in a Complete Response—A Case Report;Medicina;2024-07-12

2. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors;Current Opinion in Gastroenterology;2024-02-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP